A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 189 participants.
Also called NCT07229937
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 189 participants
- Registry
-
NCT07229937
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07229937. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-25 (actual); primary completion 2026-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia
- Condition
- Hyperlipidemia
- Intervention (Drug)
- HRS-1301
- Intervention (Drug)
- HRS-1301
- Intervention (Drug)
- HRS-1301
- Intervention (Drug)
- HRS-1301
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct07229937- Content hash
b03ec627de950b2ca1bfbfba4f9cc117c7eb1aca6184c69ad5cdc4ba9cbc2cb4